Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.65 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | HTR2B | P41595 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | PKM | P14618 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.50 |
| ▸ | ACHE | P22303 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30213582 | 1.00 | LMNA (0.65) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| Methoxymethane SCHEMBL23928712 | 0.93 | LMNA (0.59) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL10013261 | 0.90 | LMNA (0.59) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL214157 | 0.87 | LMNA (0.68) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL29872559 | 0.87 | LMNA (0.68) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL67859 | 0.87 | LMNA (0.58) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL7178394 | 0.86 | LMNA (0.52) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL15894569 | 0.85 | PKM (0.50) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL5379183 | 0.85 | LMNA (0.54) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL1536776 | 0.85 | ACHE (0.50) | LMNATRPA1CHRM1SLC6A2ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 503 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108451-A1 | COMPOSITIONS FOR THE MANAGEMENT OF HIRSUTISM | MAJEED ANJU (IN) | 2026-04-23 | — | — | US | claimed |
| EP-3731833-B1 | COMPOSITIONS CONTAINING THYMOHYDROQUINONE AND THEIR METHOD OF PREPARATION | SAMI SABINSA GROUP LTD (IN) | 2025-12-10 | — | — | EP | claimed |
| EP-4369951-B1 | NOVEL AEROSOL-GENERATING SUBSTRATE COMPRISING OREGANUM SPECIES | PHILIP MORRIS PRODUCTS SA (CH) | 2025-09-03 | — | — | EP | claimed |
| EP-4593883-A1 | COMPOSITIONS FOR THE MANAGEMENT OF HIRSUTISM | Majeed, Muhammed (IN) | 2025-08-06 | — | — | EP | claimed |
| EP-3732294-B1 | THYMOHYDROQUINONE FOR USE IN TREATING HYPERGLYCEMIA | SAMI SABINSA GROUP LTD (IN) | 2025-02-26 | — | — | EP | claimed |
| WO-2025037105-A1 | FORMULATIONS FOR TREATING HAIR LOSS AND FOR STIMULATING PIGMENTATION IN HAIR FOLLICLES | MOHAN SACH (GB) | 2025-02-20 | — | — | WO | claimed |
| US-20240373905-A1 | NOVEL AEROSOL-GENERATING SUBSTRATE COMPRISING OREGANUM SPECIES | PHILIP MORRIS PRODUCTS S.A. (CH) | 2024-11-14 | — | — | US | claimed |
| US-12053500-B2 | Compositions for management of acute nephrotoxicity | SAMI-SABINSA GROUP LIMITED (IN) | 2024-08-06 | — | — | US | claimed |
| EP-4369951-A1 | NOVEL AEROSOL-GENERATING SUBSTRATE COMPRISING OREGANUM SPECIES | Philip Morris Products S.A. (CH) | 2024-05-22 | — | — | EP | claimed |
| WO-2024073699-A1 | COMPOSITIONS FOR THE MANAGEMENT OF HIRSUTISM | MAJEED MUHAMMED (IN) | 2024-04-04 | — | — | WO | claimed |
| CN-101208071-A | Formulations | SYNTOPIX LTD (GB) | 2008-06-25 | — | — | CN | claimed |
| CN-101203205-A | Antimicrobial agents | SYNTOPIX LTD (GB) | 2008-06-18 | — | — | CN | claimed |
| WO-2008017484-A1 | NOVEL AGENTS FOR THE TREATMENT OF DISORDERS CONNECTED TO IMPAIRED NEUROTRANSMISSION | DSM IP ASSETS B.V. (NL) | 2008-02-14 | — | — | WO | claimed |
| EP-1874264-A1 | ANTIMICROBIAL FORMULATIONS | Syntopix limited (GB) | 2008-01-09 | — | — | EP | claimed |
| EP-1865915-A1 | ANTIMICROBIAL AGENTS | Syntopix limited (GB) | 2007-12-19 | — | — | EP | claimed |
| WO-2007096601-A2 | ANTIMICROBIAL FORMULATIONS COMPRISING A QUINONE AND A COPPER SALT | SYNTOPIX LIMITED (GB) | 2007-08-30 | — | — | WO | claimed |
| WO-2006100495-A1 | FORMULATIONS | SYNTOPIX LIMITED (GB) | 2006-09-28 | — | — | WO | claimed |
| WO-2006100496-A1 | ANTIMICROBIAL AGENTS | SYNTOPIX LIMITED (GB) | 2006-09-28 | — | — | WO | claimed |
| US-4487975-A | Etherification of phenols | RHONE-POULENC INDUSTRIES (FR) | 1984-12-11 | — | — | US | claimed |
| US-4425404-A | MULTILAYER, PROTECTIVE COATINGS | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 1984-01-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108451-A1 | COMPOSITIONS FOR THE MANAGEMENT OF HIRSUTISM | CYP17A1, SRD5A2, SRD5A1 | LMNA 4095/4885TRPA1 3184/4885CHRM1 1491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.